We are currently conducting a Phase 1 clinical trial of MET409 in healthy volunteers. In addition to monitoring safety and pharmacokinetics, we are assessing FXR target engagement in this trial via blood-based biomarkers.

Following completion of the Phase 1 clinical trial, we plan to evaluate MET409 as a treatment for three liver and GI diseases in parallel, beginning with NASH. We plan to submit an investigational new drug application (IND) and following acceptance, initiate a Phase 1b clinical trial in NASH before the end of 2018 and Phase 2 clinical trials in NASH, IBS-D and UC in the first half of 2019.